DCMAH

DCMAH is a **small-molecule experimental anticancer compound** identified as **(2,2-dichloroethyl)(methyl)amine hydrochloride**. It has been described as a cationic dichloro analog derived from the structural concept of dichloroacetate and has been investigated primarily in **preclinical glioblastoma models**, where it reduced tumor growth in the U87 xenograft setting. Available data suggest that DCMAH shows relatively limited direct in vitro cytotoxicity at tested concentrations and that its antitumor activity may differ mechanistically from dichloroacetate, with no confirmed evidence that it acts through the canonical pyruvate dehydrogenase kinase inhibition pathway. No clear evidence was provided of commercial development, regulatory approval, brand assignment, or an identified corporate sponsor; based on the supplied information, DCMAH appears to remain a **research-stage oncology candidate** with exploratory potential in glioblastoma and possibly other cancers.

Other names

DCMAHdichloro methylamine hydrochloride2,2-dichloroethyl methylamine hydrochloride(2,2-dichloroethyl)(methyl)amine hydrochloride